Hematolojik Malignitelerde Kemoterapi Protokolleri
ISBN 978-605-68222-4-7

RİTUKSİMAB KLORAMBUSİL

Kaynaklar:

1- Hillmen P, Gribben JG, Follows GA, et al. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: final analysis of an open-label phase II study. J Clin Oncol. 2014; 32(12):1236–1241.

2- Foà R, Del Giudice I, Cuneo A, et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol. 2014; 89(5):480–486.

3- Goede V, Fischer K, Bosch F, et al. Updated survival analysis from the CLL11 study: obinutuzumab versus rituximab in chemoimmunotherapy-treated patients with chronic lymphocytic leukemia. Abstract ASH 2015.

4- Laurenti L, Vannata B, Innocenti I, et al. Chlorambucil plus rituximab as front-line therapy in elderly/unfit patients affected by B-cell chronic lymphocytic leukemia: results of a single-centre experience. Mediterr J Hematol Infect Dis. 2013;5(1):e2013031.